Researchers have unveiled ErbB-OSV, an engineered vesicular stomatitis virus (VSV) variant designed to selectively target and destroy metastatic ovarian cancer cells while sparing normal tissue. The work reports a safety profile and potency that compare favorably with the well-studied VSV-ON-ΔM51 strain. The platform emphasizes retargeting through ErbB-associated biology to constrain oncolytic activity to tumor cells. For translational teams, the approach suggests a route to improve the therapeutic index of oncolytic virotherapy by refining targeting and signaling selectivity rather than relying solely on viral attenuation. If confirmed in clinical testing, a next wave of tumor-selective oncolytic agents could expand treatment options for patients with metastatic disease—where durable responses are still difficult to achieve.